Briumvi Injection, Solution, Concentrate
Product Images NDC 73150-150

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Briumvi (NDC 73150-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Tg Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (6 mL Carton Label)

Label for BRIUMVI (ublituximab-xiiy) injection, 150 mg/6 mL (25 mg/mL), an intravenous infusion concentrate. The label states to store refrigerated, protect from light, and that each vial contains 150 mg of ublituximab-xiiy in 6 mL solution. Manufactured by TG Therapeutics, Inc., product of Korea. The package contains one 6 mL single-dose vial.*

FDA Label Image

Principal Display Panel (6 mL Vial Label)

Label for BRIUMVI (ublituximab-xiiy) injection, an intravenous infusion solution concentrate. The vial contains 150 mg per 6 mL (25 mg/mL) in a single-dose vial. It is manufactured by TG Therapeutics, Inc. and indicates storage refrigerated at 2°C to 8°C with protection from light. The label notes no preservative and that unused portions should be discarded.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.